Skip to main content

Clinical trial ETOP 12-17 ALERT-lung

A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung)

Cancers
Organ NSCLC
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor IBCSG
EudraCT Identifier 2017-002063-17
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03445000
Inclusion criteria At least one prior platinum-based systemic regimen/ RET
Last update